Metabolic effects associated to the Highly Active Antiretroviral Therapy (HAART) in AIDS patients

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 2, 2009, Pages 130-136

  Domingos, Hamilton ^a   Da Cunha, Rivaldo Venâncio ^a   Paniago, Anamaria Mello Miranda ^a   Martins, Diego Mira ^a   Elkhoury, Eduardo Brandão ^a   De Souza, Albert Schiaveto ^b  

^a Federal Institute of Science and Technology of Mato Grosso do Sul   (Brazil)

^b Statistical Department of Mato Grosso do Sul Dom Bosco Catolic University   (Brazil)

Author keywords

AIDS; Dyslipidaemia; HAART; Insulin resistance; Metabolic effects

Indexed keywords

CHOLESTEROL; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE; LOW DENSITY LIPOPROTEIN; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAZIL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 76649085856     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702009000200012     Document Type: Article

References (33)

1. Boskurt B. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical study. Cardiovasc Toxicol 2004;4(3):243-60.
2. Tershakovee A.M., Frank I., Rader D. HIV-related lipodystrophy and related factor.Atherosclerosis 2004 May;174(1):1-10.
3. Shevitz A. Clinical perspectives on HIV- associated lipodystrophy syndrome: an update. AIDS 2001;15(15):1917-30.
4. Duong M., Cottin Y. Is there an increased risk for cardiovascular in HIV-infected patients on antiretroviral therapy. Ann Cardiol Angeiol (Paris) 2003;52(5):302-7.
5. Montague C.T., O'Rahilly. The prils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49(6):883-8.
6. Hurwitz B.E., Klimas N.G., Llabre M.M., et al. HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: role of protease inhibitor exposure. Cardiovasc Toxicol 2004;4(3):303-16.
7. Carr A. Cardiovascular risk factors in HIV - infected patients. Acquir Immune Defic Syndr 2003;34(1):S73-8.
8. Calza L., Manfredi R., Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Antimicrob Chemother 2004;53(1):10-4.
9. Barbaro G. Highly active antiretroviral therapy and the cardiovascular system: the heart of the matter. Pharmacology 2003;69(4):177-9.
10. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(adult treatment panel III - ATP III). JAMA 2001;285:2486-97.
11. American Diabetes Association Position Statement. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(1):S5-S10.
12. Shott S. Statistics for health professionals. London:W.B. Saunders Company, 1990.
13. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica - Sociedade Brasileira de Cardiologia - Arquivos Brasileiros de Cardiologia 2005;84(SI):8-28.
14. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 2002;287:356-9.
15. McNeill A.M., Rosamond W.D., Girman C.J., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28(2):385-90.
16. Dubé M.P., Stein J.H., Aberg J.A., et al. Guidelines for the Evaluation and Management of Dyslipidaemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27.
17. Fellay J., Bernasconi E., Ledergerber B., et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-7.
18. Tsiodras S., Mantzoros C., Hammer S., Samore M. Effects of protease inhibitors on hyperglycemia, hiperlipidemia and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6.
19. Green M.L. Evaluation and management of dyslipidemia in patients with HIV infection. JGIM 2002;17:797-802.
20. Duong M., Cottin Y. Is there an increased risk for cardiovascular in HIV-infected patients on antiretroviral therapy. Ann Cardiol Angeiol (Paris) 2003;52(5):302-7.
21. Mondal D., Pradhan L., Ali M., Agrawal K.C. HAART drugs induce oxidative stress in human endotelial cells and increase endotelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004;4(3):287-302.
22. Kumar P., Rodriguez-French A., Thompson M. Prospective study of hyperlipidemia in ART- naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine(3TC)/NFV Foundation for Retrovirology and human Health 2002;64.
23. Eron J.J. Jr., Murphy R.L., Peterson D. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000;14:1601-10.
24. Staszewski S, Gallant JE, Pozniak AL, Dejesus E, Suleiman JM, Miller MD, et al.. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) in combination therapy in antiretroviral- naïve patients - a 3-year randomized trial. JAMA 2004;292:191-201.
25. th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego) Washington, DC: American Society for Microbiology 1999.
26. th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, V A: Foundation for Retrovirology and Human Health 2003;328.
27. Jones C.Y. Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort. J Acquir Immune Defic Syndr 2005;40(2):202-11.
28. Brown T.T. Antiretroviral therapy and the prevalence an incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005;165(10):1179-84.
29. Wang S.M.R., Elosua C. Association of HIV- protease inhibitors with insulin resistance is related to potency of inhibition of GLUT4 and GLUT1 activity in adipocytes and myocytes. Antivir Ther 2003;8:L36.
30. Montessori V., Montaner J.S.G., Akagi L., et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004;170(2):229-38.
31. Ena J., Benito C., Yacer P., et al. Abnormal body fat distribuition and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV - infected patients. Med Clin (Barc) 2004;122(19):746-7.
32. Fichtenbaum C.J. Antiretrovirals and Cardiovascular Disease: Is HAART Bad for Your Heart?. AIDS Clinical Care 2003;15(8):69-73,76.
33. Rhew D.C., Bernal M., Aguilar D., et al. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic revision. Clin Infect Dis 2003;37(7):959-72.